Taraszka K, Groha S, King D, et al. A comprehensive analysis of clinical and polygenic germline influences on somatic mutational burden. American journal of human genetics. 2024. doi:10.1016/j.ajhg.2023.12.010
Hofman DA, Ruiz-Orera J, Yannuzzi I, et al. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. bioRxiv : the preprint server for biology. 2023. doi:10.1101/2023.05.04.539399
Arp CJ, Reynders M, Sreekanth V, et al. Photoswitchable Molecular Glues Enable Optical Control of Transcription Factor Degradation. bioRxiv : the preprint server for biology. 2023. doi:10.1101/2023.04.09.536172
Zou T, Zhou M, Gupta A, et al. deletion induces PKR-dependent cell lethality in interferon-activated cancer cells. bioRxiv : the preprint server for biology. 2023. doi:10.1101/2023.08.01.551488
Arp CJ, Reynders M, Sreekanth V, et al. Photoswitchable Molecular Glues Enable Optical Control of Transcription Factor Degradation. bioRxiv : the preprint server for biology. 2023. doi:10.1101/2023.04.09.536172
Hacken ET, Gruber M, Hernández-Sánchez M, et al. Generation of mouse models carrying B cell restricted single or multiplexed loss-of-function mutations through CRISPR-Cas9 gene editing. STAR protocols. 2023;4(4):102165. doi:10.1016/j.xpro.2023.102165
Phadnis V V, Snider J, Varadharajan V, et al. MMD collaborates with ACSL4 and MBOAT7 to promote polyunsaturated phosphatidylinositol remodeling and susceptibility to ferroptosis. Cell reports. 2023;42(9):113023. doi:10.1016/j.celrep.2023.113023
Elmarakeby HA, Trukhanov PS, Arroyo VM, et al. Empirical evaluation of language modeling to ascertain cancer outcomes from clinical text reports. BMC bioinformatics. 2023;24(1):328. doi:10.1186/s12859-023-05439-1
Kim JY, Song M, Kim MS, et al. An atlas of associations between 14 micronutrients and 22 cancer outcomes: Mendelian randomization analyses. BMC medicine. 2023;21(1):316. doi:10.1186/s12916-023-03018-y
Groves A, Ward A, Li YY, et al. Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors. Pediatric blood & cancer. 2023:e30643. doi:10.1002/pbc.30643